Anika Therapeutics | ANIK - Bienes





Bienes Cambio Fecha
Abbott USD 110.43B 23.72B 2026-03
Agenus USD 172.69M 13.76M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Insmed USD 2.1B 26.7M 2026-06
Integra LifeSciences USD 3.56B 14.24M 2026-06
Intrexon USD 73.16M 77.88M 2024-06
J&J USD 201.06B 167M 2026-06
Karyopharm Therapeutics USD 131.42M 23M 2026-03
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
MacroGenics USD 345.41M 127.54M 2026-06
Merit Medical Systems USD 2.86B 144.34M 2026-06
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 129.06B 1.04B 2026-06
Smith & Nephew USD 11.01B 321M 2026-06
Stryker USD 47.93B 1.64B 2026-06
Veracyte USD 1.49B 49.97M 2026-06
Xencor USD 724.96M 11.89M 2026-06
Zimmer Biomet Holdings USD 22.8B 76.2M 2026-06